🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are increasing worldwide, with estimates suggesting in excess of 82 million instances annually. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists hope that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

Based on data released by a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which involves an injection and a pill. The study included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous regions with limited resources.

Clinicians directly involved have expressed positive views. Having a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is deemed crucial to reduce the burden of the infection for patients and to stop the proliferation of untreatable gonorrhoea worldwide.